CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
Authors:
Open Access
- 1 March 2013
- journal article
- Published by Global Cardiology Science and Practice in Global Cardiology Science and Practice
- Vol. 2013 (1) , 5-8
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heartEMBO Molecular Medicine, 2013
- Regulation of neonatal and adult mammalian heart regeneration by the miR-15 familyProceedings of the National Academy of Sciences, 2012
- Mammalian heart renewal by pre-existing cardiomyocytesNature, 2012
- Functional screening identifies miRNAs inducing cardiac regenerationNature, 2012
- Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trialThe Lancet, 2012
- SCIPIO brings new momentum to cardiac cell therapyThe Lancet, 2011
- RETRACTED: Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trialThe Lancet, 2011
- Evidence for Cardiomyocyte Renewal in HumansScience, 2009
- Controlled Delivery of Basic Fibroblast Growth Factor Promotes Human Cardiosphere-Derived Cell Engraftment to Enhance Cardiac Repair for Chronic Myocardial InfarctionJACC, 2008
- Therapeutic Delivery of Cyclin A2 Induces Myocardial Regeneration and Enhances Cardiac Function in Ischemic Heart FailureCirculation, 2006